Company intelligence / Profile preview

Autocrat

London, United Kingdom

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T-cell therapies for the treatment of cancer and autoimmune diseases. The company utilizes a proprietary suite of T-cell programming technologies to engineer precisely targeted, controlled, and highly active T-cell products. Its lead candidate, obe-cel (Aucatzyl), recently received FDA approval for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus aims to provide curative treatments with improved safety profiles compared to first-generation CAR-T therapies.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Partnerships

BioNTechModernaBristol Myers Squibb

Beyond the preview

Go deeper on Autocrat.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autocrat.

Explore the full profile